Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments.
Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments.
复制标题
青光眼患者从单一疗法转向拉坦前列素的眼压、安全性和生活质量。
DOI：
10.1089/108076803322472971
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
W. C. Stewart
中科院分区：
文献类型：
--
作者：
T. Zimmerman;W. C. Stewart
目的
评价需要改变既往治疗并改为拉坦前列素的高眼压或开角型青光眼患者的疗效、安全性和生活质量。
方法
一项前瞻性、多中心、活性、历史对照试验，合格患者既往接受拉坦前列素0.005%替代治疗，并随访长达6个月。
结果
3179例患者纳入意向治疗分析。在所有患者中，拉坦前列素将眼内压（IOP）从20.1 ± 3.9 mmHg降至17.1 ± 3.5 mmHg（p< 0.0001），与之前的单药治疗相比：阻断剂（-3.0 +/- 3.5，n = 1976），α-激动剂（-3.6 +/- 3.7，n = 581），缩瞳剂（-2.8 +/-3.0，n = 21）、碳酸酐酶抑制剂（-3.2 +/-3.5，n = 198）和其他前列腺素类似物（-1.6 +/-3.7，n = 402）。拉坦前列素最常见的眼部不良事件为结膜充血（n = 66，发生率2.0%），最常见的全身不良事件为头痛（n = 9，0.2%）。在6个月的治疗间隔内，89.8%的患者维持拉坦前列素治疗。在征集性症状调查中，与既往治疗相比，患者显示出对拉坦前列素的偏好，原因如下：（取决于产品）干燥、视力模糊、流泪、滴注时刺痛、结痂、瘙痒、疲劳、头晕、沮丧和口干（p < 0.005）。
结论
拉坦前列素通常可降低IOP，副作用有限，改善许多生活质量指标，并在需要替代既往单药治疗的患者中维持治疗。
PURPOSE
To evaluate the efficacy, safety and quality of life in ocular hypertensive or open-angle glaucoma patients who required alteration in previous therapy and were changed to latanoprost.
METHODS
A prospective, multicenter, active, historical controlled trial in which qualified patients had previous therapy substituted with latanoprost 0.005% and were followed for up to 6 months.
RESULTS
3179 patients were included in the intent-to-treat analysis. In all patients latanoprost reduced the intraocular pressure (IOP) from 20.1 +/- 3.9 to 17.1 +/- 3.5 mm Hg (p< 0.0001) and when compared to previous monotherapies: beta-blockers (-3.0 +/- 3.5, n = 1976), alpha-agonists (-3.6 +/- 3.7, n = 581), miotics (-2.8 +/- 3.0, n = 21), carbonic anhydrase inhibitors (-3.2 +/- 3.5, n = 198), and other prostaglandin analogs (-1.6 +/- 3.7, n = 402). The most common ocular adverse event with latanoprost was conjunctival hyperemia (n = 66, 2.0% incidence) and the most common systemic adverse event was headache (n = 9, 0.2%). Over the 6-month treatment interval 89.8% of patients were maintained on latanoprost. On the solicited symptom survey patients showed a preference for latanoprost compared to previous therapy for several reasons: (depending on the product) dryness, blurred vision, tearing, stinging on instillation, crusting, itching, fatigue, dizziness, despondency and dry mouth (p < 0.005).
CONCLUSION
Latanoprost generally provides reduced IOP, limited side-effects, improvement in many quality of life measures and is maintained in patients who required a substitution from previous monotherapy.